Cisplatin
Publication: Annals of Internal Medicine
Volume 100, Number 5
Abstract
Cisplatin is a metal coordination compound that was approved for clinical use in treating testicular cancer 5 years ago. Although early trials showed marked gastrointestinal and renal toxicities, treatment-related morbidity has been significantly alleviated with modern antiemetic therapy and adequate pretreatment hydration. More recent clinical studies of cisplatin have shown a broad range of activity and provide a better understanding of the drug's pharmacology, mechanism of action, and toxicity. Variations in the dosage and mode of administration as well as development of cisplatin analogues are being currently studied.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
ROSENBERG B, VAN CAMP L, and KRIGAS T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698-9.
2.
ROBERTS J. CISPLATIN. In: PINEDO HM, ed. Cancer Chemotherapy. Amsterdam: Excerpta Medica; 1982:95-117.
3.
ZWELLING L and KOHN K. Mechanism of action of cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1979;63:1439-44.
4.
LIPPARD S. New chemistry of an old molecule: cis-(Pt(NH3)2Cl2). Science. 1982;218:1075-82.
5.
SCHABEL F, TRADER M, LASTER W, CORBETT T, and GRISWOLD D. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979;63:1459-73.
6.
CARDE P and LAVAL F. Effect of cis-dichlorodiammineplatinum II and Xrays on mammalian cell survival. Int J Radiat Oncol Biol Phys. 1981;7:929-33.
7.
LOKICH J. Phase I study of cis-diamminedichloroplatinum (II) administered as a constant 5-day infusion. Cancer Treat Rep. 1980;64:905-8.
8.
MORAN R and STRAUS M. Effects of pulse and continuous intravenous infusion of cis-diamminedichloroplatinum on L1210 leukemia in vivo. Cancer Res. 1981;41:4993-6.
9.
BOZZINO J, PRASAD V, and KORIECH O. Avoidance of renal toxicity by 24-hour infusion of cisplatin. Cancer Treat Rep. 1981;65:351-2.
10.
EARHEART R. Instability of cis-dichlorodiammineplatinum (H) in dextrose solution. Cancer Treat Rep. 1978;62:1105-6.
11.
LITTERST C. Alterations in the toxicity of cis-dichlorodiammineplatinum II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol. 1981;61:99-108.
12.
BELT R, HIMMELSTEIN K, PATTON T, BANNISTER S, STERNSON L, and REPTA A. Pharmacokinetics of non-protein-bound platinum species following administration of cisdichlorodiammineplatinum (II). Cancer Treat Rep. 1979;63:1515-21.
13.
GORMLEY P, BULL J, LEROY A, and CYSYK R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979;25:351-7.
14.
GOUYETTE A, LEMOINE R, and ADHEMAR J. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep. 1981;65:665-8.
15.
PRETORIUS R, PETRILLI E, KEAN C, FORD L, HOESCHELE J, and LAGASSE L. Comparison of the IV and IP routes of administration of cisplatin in dogs. Cancer Treat Rep. 1981;65:1055-62.
16.
HOWELL S, PFEIFLE C, and WUNG W. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845-51.
17.
CASPER E, KELSEN D, ALCOCK N, and LEWIS J. IP cisplatin in patients with malignant ascites: pharmocokinetic evaluation and comparison with the IV route. Cancer Treat Rep. 1983;67:235-8.
18.
GORMLEY P, GANGJI D, WOOD J, and POPLACK D. Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol. 1981;5:247-60.
19.
BERMAN I and MANN M. Seizures and transient cortical blindness associated with cisplatinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45:764-6.
20.
BONNEM E, LITTERST C, and SMITH F. Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep. 1982;66:1661-3.
21.
BRUCKNER H, WALLACH R, and COHEN C. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol. 1981;12:64-7.
22.
SAMSON M, RIVKIN S, and JONES S. Dose-response and dosesurvival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer. 1984;53:1029-35.
23.
BONOMI P, BRUCKNER H, COHEN C, MARSHALL R, BLESSING J, and SLAYTON R. A randomized trial of three cisplatin regimens in squamous cell carcinoma of the cervix [Abstract]. Proc Am Soc Clin Oncol. 1982;1:110.
24.
OZOLS R, CORDEN B, JACOBS J, WESLEY M, OSTCHEGA Y, and YOUNG R. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19-24.
25.
CHIUTEN D, VOGL S, KAPLAN B, and CAMACHO F. IS there cumulative or delayed toxicity from cis-platinum? Cancer. 1983;52:211-4.
26.
VON HOFF D, SCHILSKY R, and REICHERT C. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep. 1979;63:1527-31.
27.
VOGL S, ZARAVINOS T, and KAPLAN B: Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer. 1980;45:11-5.
28.
WIESENFELD M, REINDERS E, CORDER M, YOO T, DIETZ B, and LOVETT J. Successful retreatment with cis-dichlorodiammineplatinum (II) after apparent allergic reactions. Cancer Treat Rep. 1979;63:219-21.
29.
SEIGEL L and LONGO D. The control of chemotherapy-induced emesis. Ann Intern Med. 1981;95:352-9.
30.
VINCENT B, MCQUISTON D, EINHORN L, NAGY C, and BRAMES M. Review of cannabinoids and their antiemetic effectiveness. Drugs. 1983;25:52-62.
31.
GRALLA R, ITRI L, and PISKO S. Antiemetic efficacy of highdose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305:905-9.
32.
WEISS R and POSTER D. The renal toxicity of cancer chemotherapeutic agents. Cancer Treat Rev. 1982;9:37-56.
33.
COMIS R. Cisplatin nephrotoxicity: the effect of dose, schedule, and hydration scheme. In: PRESTAYKO AW, CROOKE ST, CARTER SK, eds. Cisplatin: Current Status and New Developments. New York: Academic Press, Inc. ; 1980: 485-94.
34.
MEIJER S, SLEIJFER D, and MULDER N. Some effects of combination chemotherapy with cisplatinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer. 1983;51:2035-40.
35.
DENTINO M, LUFT F, YUM M, WILLIAMS S, and EINHORN L. Long term effects of cis-diamminedichloride platinum (CDDP) on renal structure and function in man. Cancer. 1978;41:1274-81.
36.
MARKHAM M and TRUMP D. Nephrotoxicity with cisplatin and antihypertensive medications [Letter]. Ann In tern Med. 1982;96:257.
37.
HAAS A, ANDERSON L, and LAD T. The influence of aminoglycosides on nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J Infect Dis. 1983;147:363.
38.
WADE J, SCHIMPFF S, and WIERNICK P. Aminoglycoside-cephalosporin associated nephrotoxicity. Clin Res. 1979;27:481A.
39.
SCHILSKY R and ANDERSON T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979;90:929-31.
40.
BLACHLEY J and HILL J. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med. 1981;95:628-32.
41.
DRASGA R, EINHORN L, WILLIAMS S, and PATEL D. Fertility after chemotherapy for testicular cancer. J Clin Oncol. 1983;1:179-83.
42.
ROTHMAN S and WEICK J. Cisplatin toxicity for erythroid precursors [Letter]. N Engl J Med. 1981;304:360.
43.
NOWROVSIAN M and SCHMIDT C. Effects of cisplatin in different haemopoetic progenitor cells in mice. Br J Cancer. 1982;46:397-402.
44.
GETAZ E, BECKLEY S, FITZPATRICK J, and DOZIER A. Cisplatin-induced hemolysis. N Engl J Med. 1980;302:334-5.
45.
NGOYEN B and JAFEE N. Cisplatin-induced anemia. Cancer Treat Rep. 1981;65:1121.
46.
LEVI A, ARONEY R, and DALLEY D. Haemolytic anemia after cisplatin treatment. Br Med J. 1981;282:2003-4.
47.
GRIFFIN J and GARNICK M. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer. 1981;48:1539-49.
48.
OSTROW S, HAHN D, WIESNIK P, and RICHARDS R. Cis-dichlorodiammineplatinum (II) therapy. Cancer Treat Rep. 1978;62:1591-4.
49.
ROSSOF A, TALLEY R, and STEPHENS R. Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Cancer Treat Rep. 1979;63:1557-64.
50.
MEAD G, ARNOLD A, GREEN J, MACBETH F, WILLIAMS C, and WHITEHOUSE J. Epileptic seizures associated with cisplatin administration. Cancer Treat Rep. 1982;66:1719-22.
51.
BERMAN I and MANN M. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45:764-6.
52.
REDDEL R, KEFFORD R, GRANT J, COATES A, FOX R, and TATTERSALL M. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19-23.
53.
SCHAEFER S, WRIGHT C, POST J, and FRENKEL E. Cis-platinum vestibular toxicity. Cancer. 1981;47:847-59.
54.
MCHANEY V, THIBADOUX M, HAYES F, and GREEN A. Hearing loss in children receiving cisplatin chemotherapy. J Pediatrics. 1983;102:314-7.
55.
VOGELZANG N, BOSL G, JOHNSON K, and KENNEDY B. Raynaud's phenomena: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92.
56.
DRASGA R, EINHORN L, and WILLIAMS S. The chemotherapy of testicular cancer. CA. 1982;32:66-77.
57.
WILLIAMS S and EINHORN L. Etoposide salvage therapy for refractory germ cell tumors: an update. Cancer Treat Rev. 1982;9A:67-71.
58.
WEISS R, DEWYS W, and GREEN S. Adjuvant chemotherapy and indicators of relapse in stages I and II non-seminomatous testicular carcinoma [Abstract]. Proc Int Cong Chemother. 1983;272:32-5.
59.
PAULSON D, PEREZ C, and ANDERSON T. Genitourinary malignancies. In: DEVITA VT, HELLMAN S, ROSENBERG SA, eds. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott; 1982:732-85.
60.
EINSTEIN A, SOLOWAY M, CORDER M, BONNEY W, and COOMBS J. Diamminedichloroplatinum (DDP) versus DDP plus cyclophosphamide for metastatic bladder carcinoma: a National Bladder Cancer Cooperative Group A Study [Abstract]. Proc Am Soc Clin Oncol. 1981;21:461.
61.
YAGODA A. Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat Rep. 1979;63:1565-72.
62.
YAGODA A, WATSON R, and NATALE R. A critical analysis of response criteria in patients with prostatic cancer treated with cisdiamminedichlorideplatinum (II). Cancer. 1979;44:1553-62.
63.
SOLOWAY M, BECKLEY S, and BRADY M. A comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral Area. J Urol. 1983;129:56-61.
64.
QUAZI R and KHANDEKAR J. Phase II study of cisplatin for metastatic prostatic carcinoma: an Eastern Cooperative Group Study. Am J Clin Oncol. 1983;6:203-5.
65.
HOGAN W and YOUNG R. Gynecologic malignancies. In: PINEDO HM, ed. Cancer Chemotherapy. Amsterdam: Excerpta Medica, 1982: 309-38.
66.
KATZ M, SCHWARTZ P, KAPP D, and LUIKART S. Epithelial carcinoma of the ovary: current strategies. Ann Intern Med. 1981;95:98-111.
67.
MANGIONI C, BOLIS G, BORTOLOZZI G, SESSA C, and GARATTINI S. Cisdichlorodiammineplatinum, adriamycin, cyclophosphamide vs. hexamethylmelamine, adriamycin, cyclophosphamide in advanced ovarian cancer [Absract]. Proc Am Assoc Cancer Res. 1980;21:149.
68.
OMURA G, EHRLICH C, and BLESSING J. A randomized trial of cyclophosphamide plus adriamycin with or without cisplatinum in ovarian cancer [Abstract]. Proc Am Soc Clin Oncol. 1982;1:104.
69.
EINHORN L, WILLIAMS S, STEVENS E, BOND W, and CHENOWETH L. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single agent sequential chemotherapy in non-small cell lung cancer. Cancer Treat Rep. 1982;66:2005-11.
70.
HANSEN H and RORTH M. Lung Cancer. In: PINEDO HM, ed. Cancer Chemotherapy. Amsterdam: Excerpta Medica; 1982:249-71.
71.
BHUCHAR V and LANZOTTI V. High-dose cisplatin for lung cancer. Cancer Treat Rep. 1982;66:375-6.
72.
CASPER E, GRALLA R, KELSEN D, CVITKOVIC E, and GOLBEY R. Phase II study of high-dose cis-dichlorodiammineplatinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep. 1979;63:2107-9.
73.
GRALLA R, CASPER E, and KELSEN D. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med. 1981;95:414-20.
74.
SIEROCKI J, HILARIS B, and HOPFAN S. cis-Dichlorodiammineplatinum (II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep. 1979;63:1593-7.
75.
KLASTERSKY J, NICAISE C, LONGEVAL E, and STRYCKMANS P. Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Cancer. 1982;50:652-8.
76.
HONG W and BROMER R. Chemotherapy in head and neck cancer. N Engl J Med. 1983;308:75-9.
77.
KISH J, DRELICHMAN A, and JACOBS J. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1982;66:471-4.
78.
HONG W, SCHAEFER S, and ISSELL B. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52:206-10.
79.
WILLIAMS S, EINHORN L, and VELEZ-GARCIA E. Chemotherapy of head and neck cancer: comparison of cisplatin plus vinblastine plus bleomycin versus methotrexate [Abstract]. Proc Am Soc Clin Oncol. 1982;1:202.
80.
ROSENBERG S, SUIT H, BAKER L, and ROSEN G. Sarcomas of the soft tissue and bone. In: DEVITA VT, HELLMAN S, ROSENBERG SA, eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott; 1982:1036-93.
81.
ROSEN G, CAPARROS B, and HUVOS A. Preoperative chemotherapy for osteogenic carcinoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-30.
82.
JAFFE N, KNOPP J, and CHUANG V. Osteosarcoma: intra-arterial treatment in the primary tumor with cis-diamminedichloroplatinum (II) (CDP): angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51:402-7.
83.
BRENNER J, MAGILL G, SORDILLO P, CHENG E, and YAGODA A. Phase II trial of cisplatin (CDDP) in previously treated patients with advanced soft tissue sarcoma. Cancer. 1982;50:2031-3.
84.
THIGPEN T, SHINGLETON H, HOMESLY H, and BLESSING J. Phase II trial of cis-diamminedichloroplatinum (DDP) in treatment of advanced or recurrent mixed mesodermal sarcoma of the uterus [Abstract]. Proc Am Soc Clin Oncol. 1982; 1:110.
85.
CAVALLI F, JUNGI W, NISSEN N, PAJAK T, COLEMAN M, and HOLLAND J. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the Cancer and Acute Leukemia Group B. Cancer. 1981;48:1927-30.
86.
O'CONNELL M, ANDERSON J, and MERRILL J. Comparative trial of two teniposide based combination chemotherapy regimens for the treatment of advanced malignant lymphomas. Cancer Treat Rep. 1982;66:2021-5.
87.
LEIPMAN M, WHEELER R, ZUCKERMAN K, and LOBUGLIO A. Combination chemotherapy of refractory lymphoma with cis-dichlorodiammineplatinum, vinblastine, and bleomycin. Cancer. 1982;50:2736-9.
88.
KELSEN D. Treatment of advanced esophageal cancer. Cancer. 1982;50:2576-81.
89.
VOGL S, GREENWALD E, and KAPLAN B. Effective chemotherapy for esophageal cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum (II). Cancer. 1981;48:2555-8.
90.
LAD T. Platinum, mitomycin-C, and bleomycin chemotherapy of esophageal carcinoma [Abstract]. Proc Am Soc Clin Oncol. 1980;21:419.
91.
LACANE A, IZARZUGAZA I, and APARICIO L. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol. 1983;6:35-8.
92.
WOOLEY P, SMITH F, and ESTEVEZ R. A phase II trial of 5-FU, adriamycin and cisplatin (FAP) in advanced gastric cancer [Abstract]. Proc Am Soc Clin Oncol. 1981;22:455.
93.
GISSELBRECH T, SMITH F, and WOOLLEY P. Phase II trial of FAP (5-fluorouracil, adriamycin, and cis-diammdichloroplatinum) chemotherapy for advanced measurable pancreatic cancer and adenocarcinoma of unknown primary origin [Abstract]. Proc Am Soc Clin Oncol. 1981;22:454.
94.
FRIEDMAN M. The use of intravenous cisplatin in various malignancies. In: PRESTAYKO AW, CROOKE ST, CARTER SK, eds. Cisplatin: Current Status and New Developments. New York: Academic Press; 1980:459-64.
95.
FISHER W, HERBST K, SIMS J, and CRITCHFIELD D. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1978;62:91-7.
96.
PRATT C, HAYES A, and GREEN A. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep. 1981;65:1021-6.
97.
KAMALAKAR P, FREEMAN A, HIGBY D, WALLACE J, and SINKS L. Clinical response and toxicity with cis-dichlorodiammineplatinum (II) in children. Cancer Treat Rep. 1977;61:835-9.
98.
TATTERSALL M, LANDER H, and BAIN B. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust. 1980;1:419-21.
99.
NEEDLES B, KEMENY N, and URMACHER C. Malignant thymoma: renal metastases responding to cis-platinum. Cancer. 1981;42:223-6.
100.
COCCONI G, BONI C, and CUOMO A. Long-lasting response to cis-platinum in recurrent malignant thymoma. Cancer. 1982;49:1985-7.
101.
KHAN A, D'SOUZA B, and WHARAM M. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep. 1982;66:2013-20.
102.
AL-SARRAF M, FLETCHER W, and OISHI N. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group Study. Cancer Treat Repi. 1982;66:31-5.
103.
NATHANSON L, KAUFMAN S, and CAREY R. Vinblastine, infusion, bleomycin and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer. 1981;48:1290-4.
104.
CREAGAN E, AHMAN D, SCHUTT A, and GREEN S. Phase II study of the combination of vinblastine, bleomycin and cisplatin in advanced malignant melanoma. Cancer Treat Rep. 1981;66:567-9.
105.
YAP H, SALEM P, and HORTOBAGYI G. Phase II study of cisdichlorodiammine-platinum (II) in advanced breast carcinoma. Cancer Treat Rep. 1978;62:405-8.
106.
BULL J, ANDERSON T, LIPPMAN M, CASSIDY J, GORMLEY P, and YOUNG R. A phase II trial of cis-dichlorodiammineplatinum (II) in breast and ovarian carcinoma [Abstract]. Proc Am Assoc Cancer Res. 1978;19:87.
107.
SAMAL B, VAITKEVICIUS V, and SINGHAKOWINTA A. Cis-diamminedichloroplatinum in advanced breast and colorectal carcinoma [Abstract]. Proc Am Soc Clin Oncol. 1978;19:347.
108.
OSTROW S, EGORIN M, AISNER J, BACHUR N, and WIESNIK P. Highdose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials. 1980;3:23-7.
109.
FORASTIERE A, HAKES T, WITTES J, and WITTES R. Cis-platin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982;5:243-7.
110.
ROSENBERG B. Anticancer activity of cis-diammineplatinum (II) and some relevant chemistry. Cancer Treat Rep. 1979;63:1433-8.
111.
ROSE W, SCHURIG J, HUFTALEN J, and BRADNER W. Antitumor activity and toxicity of cisplatin analogs. Cancer Treat Rep. 1982;66:135-46.
112.
KELSEN D, SCHER H, and ALCOCK N. Phase I clinical trial and pharmacokinetics of 4'-Carboxyphthalato-(1,2-diaminocyclohexane) platinum (II). Cancer Res. 1982;42:4831-5.
113.
PENDYALA L, COWENS J, and CREAVEN P. Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine (IV) in the dog. Cancer Treat Rep. 1982;66:509-16.
114.
CURT G, GRYGIEL J, and WEISS R. A phase I and pharmacokinetic study of CBDCA (NSC-241240) [Abstract]. Proc Am Soc Clin Oncol. 1983;2:21.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 100 • Number 5 • 1 May 1984
Pages: 704 - 713
History
Published in issue: 1 May 1984
Published online: 1 December 2008
Keywords
Copyright
© 1984 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Cisplatin. Ann Intern Med.1984;100:704-713. doi:10.7326/0003-4819-100-5-704
Cisplatin. Ann Intern Med.1984;100:704-713. doi:10.7326/0003-4819-100-5-704
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.